You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昭衍新藥(06127.HK)斥5000萬美元購買JOINN Biologics Inc. 4411.6萬股B+輪優先股
格隆匯 12-10 20:10

格隆匯12月10日丨昭衍新藥(06127.HK)公吿,於2021年12月10日,作為目標公司JOINN Biologics Inc. B+輪融資的一環,公司(連同其他人士)與目標公司訂立購股協議,據此,公司已同意購買,而目標公司已同意發行及出售4411.6萬股B+輪優先股,佔目標公司已發行股本約4.76%,總代價為5000萬美元。購股協議的其他訂約方包括目標附屬公司、委託人、控股公司及天使投資者。

目標公司為一家於開曼羣島註冊成立的公司。其為全方位服務優質合約開發及製造機構(CDMO),為各種客户提供從DNA到藥品的質量、價值及上市速度。其於藥物生命週期的所有階段提供全面的服務,包括細胞系開發及MCB製造、工藝以及分析開發、配方開發、原料藥製造、藥品開發服務及商業化生產,以及材料生產的成套服務及研究性新藥(IND)支持PKPDTOX服務,所有有關服務均處於由全球監管服務支持的質量體系下。

公司表示,其科學家和工程師在廣泛的平台及新技術方面擁有超過20年的開發經驗。經考慮其發展全面服務的需要及評估CDMO行業具有廣闊的整體發展前景後,公司建議訂立交易。公司認為,長遠而言,該等交易於日後將令公司受益、落實其整體發展戰略及促進進一步拓展市場。

目標公司成立於2018年,目前處於初始業務發展階段。目標公司營運所在的CDMO行業屬重資產行業,需要鉅額投資固定資產。於過往年度,由於生產能力不足及固定成本較高,目標公司錄得淨虧損。然而,公司對於在目標公司融資及其設施擴張完成後,目標公司將從規模經濟受益及目標公司盈利能力將提高持樂觀態度。

於購買完成後,目標公司的客户將會優先向公司下達安全評估訂單,因此,公司預計將會受益自潛在客户及訂單的增長。長遠而言,其預期將增加公司的收益。同時,目標公司亦已於生物製藥CDMO領域方面累積項目經驗。透過雙方的合作,預期將會達致協同效應,並將改善公司於行業內的市場競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account